Dysplastic nevus syndrome and pancreatic cancer: A case report

Popa,Liliana Gabriela; Giurcaneanu,Calin; Nitipir,Cornelia; Popa,Ana Maria; Stoica,Cristiana; Beiu,Cristina; Tebeica,Tiberiu; Negoita,Silvius; Mihai,Mara Madalina

doi:10.3892/etm.2021.10953

Dysplastic nevus syndrome and pancreatic cancer: A case report

Authors:
- Liliana Gabriela Popa
- Calin Giurcaneanu
- Cornelia Nitipir
- Ana Maria Popa
- Cristiana Stoica
- Cristina Beiu
- Tiberiu Tebeica
- Silvius Negoita
- Mara Madalina Mihai
View Affiliations

Affiliations: Department of Dermatology, ‘Elias’ Emergency University Hospital, 011461 Bucharest, Romania, Department of Oncology, ‘Elias’ Emergency University Hospital, 011461 Bucharest, Romania, Department of Oncologic Dermatology, ‘Elias’ Emergency University Hospital, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Dermatopathology, ‘Dr. Leventer’ Centre, 011216 Bucharest, Romania, Department of Anaesthesiology and Intensive Care, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania
Published online on: November 8, 2021 https://doi.org/10.3892/etm.2021.10953
Article Number: 31

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple primary cancers may occur in the same patient, with a prevalence that follows an ascendant trend. Their development is dictated by a complex interplay between a variety of factors, both patient‑dependent and external. The case of a 38‑year‑old female patient diagnosed and treated for pancreatic cancer (PC) is presented in whom the digital dermoscopic monitoring of melanocytic nevi revealed a marked change of two nevi that acquired rapidly highly atypical features. They were surgically excised and the histopathological examination revealed two completely excised dysplastic compound nevi. Clinicians should be aware of the strong association between dysplastic nevus syndrome and PC, a malignancy associated with an extremely poor prognosis. Familial atypical multiple mole melanoma syndrome (FAMMM) predisposes to the development of melanoma, pancreatic cancer and other neoplasms. The common genetic background of PC and hereditary melanoma is discussed and the importance of regular skin checkup and screening for PC in these patients is underlined.

View Figures

View References

1	Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T and Omlin A: Multiple primary tumours: Challenges and approaches, a review. ESMO Open. 2(e000172)2017.PubMed/NCBI View Article : Google Scholar
2	Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H (eds), et al: SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, MD, 2010. Available from: http://seer.cancer.gov/csr/1975_2007.
3	Leone G, Pagano L, Ben-Yehuda D and Voso MT: Therapy-related leukemia and myelodysplasia: Susceptibility and incidence. Haematologica. 92:1389–1398. 2007.PubMed/NCBI View Article : Google Scholar
4	Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JYN, Wang JC and Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA. 104:11014–11019. 2007.PubMed/NCBI View Article : Google Scholar
5	Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, et al: Multi-institutional validation study of the American joint commission on cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 265:185–191. 2017.PubMed/NCBI View Article : Google Scholar
6	Kang MJ, Jang JY, Chang YR, Kwon W, Jung W and Kim SW: Revisiting the concept of lymph node metastases of pancreatic head cancer: Number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol. 21:1545–1551. 2014.PubMed/NCBI View Article : Google Scholar
7	Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, et al: Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer. 83:441–448. 1999.PubMed/NCBI View Article : Google Scholar
8	Bergman W, Watson P, de Jong J, Lynch HT and Fusaro RM: Systemic cancer and the FAMMM syndrome. Br J Cancer. 61:932–936. 1990.PubMed/NCBI View Article : Google Scholar
9	Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D IV and Organic SM: Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 100:350S–355S. 1993.PubMed/NCBI View Article : Google Scholar
10	Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 333:970–974. 1995.PubMed/NCBI View Article : Google Scholar
11	Swerdlow AJ, Storm HH and Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer. 61:773–779. 1995.PubMed/NCBI View Article : Google Scholar
12	Bergman W, Palan A and Went LN: Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome. Ann Hum Genet. 50:249–258. 1986.PubMed/NCBI View Article : Google Scholar
13	Gabree M, Patel D and Rodgers L: Clinical applications of melanoma genetics. Curr Treat Options Oncol. 15:336–350. 2014.PubMed/NCBI View Article : Google Scholar
14	Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, et al: High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66:9818–9828. 2006.PubMed/NCBI View Article : Google Scholar
15	Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, et al: Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet. 44:99–106. 2007.PubMed/NCBI View Article : Google Scholar
16	Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, Neering H and Lynch JF: Tumour spectrum in the FAMMM syndrome. Br J Cancer. 44:553–560. 1981.PubMed/NCBI View Article : Google Scholar
17	Fusaro RM, Lynch HT, Lynch JF and Madsen NJ: Phenotypic variation and systemic cancer in the FAMMM syndrome. Pigment Cell Res. 1:152–157. 1988.
18	Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P and Ghiorzo P: Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 36:77–90. 2017.PubMed/NCBI View Article : Google Scholar
19	Whelan AJ, Bartsch D and Goodfellow PJ: Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 333:975–977. 1995.PubMed/NCBI View Article : Google Scholar
20	Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:27–32. 1994.PubMed/NCBI View Article : Google Scholar
21	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993.PubMed/NCBI View Article : Google Scholar
22	Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet. 10:351–353. 1995.PubMed/NCBI View Article : Google Scholar
23	Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, et al: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 94:894–903. 2002.PubMed/NCBI View Article : Google Scholar
24	Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET and Bergman W: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 87:809–811. 2000.PubMed/NCBI
25	de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, et al: Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 14:7151–7157. 2008.PubMed/NCBI View Article : Google Scholar
26	Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, et al: Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 34:2010–2019. 2016.PubMed/NCBI View Article : Google Scholar
27	Bergman W and Gruis N: Familial melanoma and pancreatic cancer. N Engl J Med. 334:471–472. 1996.PubMed/NCBI
28	van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR and Gruis NA: Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 69:774–779. 2001.PubMed/NCBI View Article : Google Scholar
29	Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, et al: Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: A GenoMEL study. J Natl Cancer Inst. 102:1568–1583. 2010.PubMed/NCBI View Article : Google Scholar
30	Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al: Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun. 8(15034)2017.PubMed/NCBI View Article : Google Scholar
31	Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, et al: Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. Genes Chromosomes Cancer. 57:564–572. 2018.PubMed/NCBI View Article : Google Scholar
32	Fortes C, Mastroeni S, Melchi F, Anzidei P, Innocenzi L, Giovinazzo R, Antonelli G, Pasquini P and Venanzetti F: P5 polymorphisms in GSTM1, GSTT1, coffee consumption and cutaneous melanoma risk. Melanoma Res. 20:e45–e46. 2010.
33	Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, et al: Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 45:3271–3281. 2009.PubMed/NCBI View Article : Google Scholar
34	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
35	Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W and Vandenbroucke JP: Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol. 110:788–792. 1998.PubMed/NCBI View Article : Google Scholar
36	Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, Lynch JF, Fusaro LR, Fusaro RM and Ghadirian P: Familial pancreatic cancer: A review. Semin Oncol. 23:251–275. 1996.PubMed/NCBI
37	Brentnall TA, Bronner MP, Byrd DR, Haggitt RC and Kimmey MB: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 131:247–255. 1999.PubMed/NCBI View Article : Google Scholar